Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19532351 | 0.94 | FAAH (0.43) | FAAHCNR1CNR2DNM1CASP2 | |
| SCHEMBL20202710 | 0.90 | FAAH (0.42) | FAAHCNR1CNR2DNM1CASP2 | |
| SCHEMBL20048945 | 0.84 | MEN1 (0.47) | FAAHCNR1CNR2MEN1KMT2A | |
| SCHEMBL5964787 | 0.80 | FAAH (0.65) | FAAHCNR1CNR2DNM1CASP2 | |
| SCHEMBL15868092 | 0.77 | ADRA1A (0.47) | KDM4E | |
| SCHEMBL16111202 | 0.77 | S1PR1 (0.46) | MEN1KMT2A | |
| SCHEMBL10950026 | 0.76 | AKR1B1 (0.56) | MEN1MAPTKMT2A | |
| SCHEMBL22274917 | 0.76 | CNR1 (0.41) | FAAHCNR1NAAA | |
| SCHEMBL14576902 | 0.75 | CASP2 (0.64) | FAAHCNR1DNM1CASP2EPHX2 | |
| SCHEMBL16359431 | 0.75 | DNM1 (0.61) | FAAHCNR1DNM1CASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10023614-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | PROTAGONIST THERAPEUTICS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20180099995-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9809623-B2 | α4β7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9714270-B2 | a4B7 integrin thioether peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9624268-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9518091-B2 | A4B7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. | 2016-12-13 | — | — | US | disclosed |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160152664-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20140294901-A1 | NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | ITGB7, EPCAM, ITGB4 | FAAH 4863/4885CNR1 4215/4885CNR2 4411/4885 |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FAAH 4052/4885CNR1 3747/4885CNR2 4088/4885 |
| US-20180099995-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, EPB41 | FAAH 4811/4885CNR1 3847/4885CNR2 3897/4885 |
| US-20230129095-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | FAAH 2522/4885CNR1 2205/4885CNR2 2516/4885 |
| US-20160145306-A1 | ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES | IL23R, IL1RN, VIP | FAAH 2786/4885CNR1 1988/4885CNR2 2138/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | FAAH 1151/4885CNR1 1571/4885CNR2 1432/4885 |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | VCAM1, EPCAM, ICAM1 | FAAH 3934/4885CNR1 1794/4885CNR2 1784/4885 |
| US-10023614-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | FAAH 3236/4885CNR1 2514/4885CNR2 2631/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | FAAH 2406/4885CNR1 3642/4885CNR2 3879/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | FAAH 2522/4885CNR1 2205/4885CNR2 2516/4885 |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | FAAH 4711/4885CNR1 3620/4885CNR2 3231/4885 |
| US-20160152664-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | FAAH 4052/4885CNR1 3747/4885CNR2 4088/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | FAAH 4721/4885CNR1 3749/4885CNR2 3753/4885 |
| US-20140294901-A1 | NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, CD2BP2 | FAAH 4481/4885CNR1 4147/4885CNR2 4301/4885 |
| US-10035824-B2 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | IL23R, IL1RN, VIP | FAAH 3236/4885CNR1 2514/4885CNR2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.